Streetbeat News

Products Services

ICL

SeaStar Medical has reported significant progress in its pivotal trial for adult acute kidney injury (AKI), with 46 subjects enrolled. The trial is assessing the safety and efficacy of the Selective Cytopheretic Device for ICU patients.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:31 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) has presented promising preclinical research on its non-hallucinogenic psychedelic compound, EB-003, for treating anxiety and depression. The company plans to file an IND application by Q3 2025 and start clinical trials by the end of 2025.

Portfolio Pulse from Jelena Martinovic

September 25, 2024 | 12:30 pm

AAPL

AFRM

AMZN

BBY

COST

EA

PYPL

SNE

SQ

WMT

XRT

Adobe forecasts a record $240.8 billion in e-commerce spending this holiday season, driven by consumer splurging and discounts. Electronics, apparel, and furniture will see significant sales, with mobile and BNPL purchases rising. Companies like Apple, Sony, Amazon, Best Buy, Walmart, and Costco are expected to benefit.

Portfolio Pulse from Shanthi Rexaline

September 25, 2024 | 12:29 pm

GLMD

Galmed Pharmaceuticals has published the one-year results of its Phase 3 trial of Aramchol, showing significant anti-fibrotic effects in patients with NASH and fibrosis. The study, involving 150 patients, was published in Hepatology.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:21 pm

BABA

GVIP

JTEK

LI

NVDA

XPEV

Alibaba's Apsara Conference showcased AI advancements with participation from Nvidia and XPeng. Despite US sanctions, Alibaba continues to push its AI initiatives and partnerships, including with XPeng and Nvidia. Alibaba's stock has risen over 11% in the past year.

Portfolio Pulse from Anusuya Lahiri

September 25, 2024 | 12:16 pm

AIMD

Ainos shares rise following approval from the National Taiwan University Hospital's Institutional Review Board for a clinical trial on treating oral warts in HIV-positive patients.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:14 pm

WINT

Windtree Therapeutics announced positive topline results from its Phase 2B SEISMiC extension study of Istaroxime in early cardiogenic shock. The study showed significant improvements in systolic blood pressure over six hours and notable secondary endpoint improvements.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

BTCUSD

Bill Maher criticizes Bitcoin mining for its high energy consumption, claiming it undermines green energy progress. He compares its environmental impact to adding millions of gas-powered cars. The debate on crypto's carbon footprint is intensifying.

Portfolio Pulse from Murtuza Merchant

September 25, 2024 | 12:10 pm

AVDL

Avadel Pharmaceuticals published data in 'Sleep Medicine' showing the efficacy of LUMRYZ in improving narcolepsy symptoms, regardless of alerting agent use. The Phase 3 REST-ON trial confirmed significant improvements in wakefulness and reduced cataplexy episodes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

ERAS

Erasca, Inc. (NASDAQ:ERAS) will present preliminary Phase 1 data for naporafenib plus trametinib in RAS Q61X mutant solid tumors at the 36th EORTC-NCI-AACR Symposium. The company is also conducting a Phase 3 trial in NRAS-mutant melanoma. A virtual R&D update for investors is scheduled for October 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:09 pm